Aspen Neuroscience CFO Meeter reports stock options

The options have expiration dates in 2035, while their disclosed vesting schedules are tied to continued service.

Accepted by SEC EDGAR 10/29/2026 - 07:55 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Aspen Neuroscience, Inc. (ASPE) Chief Financial Officer Dalen Meeter reported direct stock options to buy 101,193 common shares at an exercise price of $8.70, expiring March 12, 2035; and options covering 34,405 and 88,543 common shares at $5.74, both expiring November 25, 2035. The disclosed vesting schedules include monthly vesting subject to continued service.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider Meeter Dalen

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Holding	Stock Option (Right to Buy) F1	--	--	--
Holding	Stock Option (Right to Buy) F2	--	--	--
Holding	Stock Option (Right to Buy) F3	--	--	--

Holdings: Stock Option (Right to Buy) — 224,141 contracts (Direct)

Footnotes (3)

1. F1. The option was granted on March 13, 2025. 1/4th of the option vested and became exercisable on March 10, 2026, and 1/48th of the option shall vest equally and become exercisable on the same day of each month thereafter, subject to the Reporting Person's continued service through each vesting date.
2. F2. The option was granted on November 26, 2025. 1/4th of the option vested and became exercisable on October 1, 2026, and 1/48th of the option shall vest and become exercisable on the same day of each month thereafter, subject to the Reporting Person's continued service through each vesting date.
3. F3. The option was granted on November 26, 2025. 1/48th of the option shall vest and become exercisable on monthly anniversary beginning on December 20, 2025, subject to the Reporting Person's continued service through each vesting date.

Key Figures

Underlying common shares: 101,193 shares Underlying common shares: 34,405 shares Underlying common shares: 88,543 shares +4 more

7 metrics

Underlying common shares 101,193 shares Direct option expiring March 12, 2035

Underlying common shares 34,405 shares Direct option expiring November 25, 2035

Underlying common shares 88,543 shares Direct option expiring November 25, 2035

Exercise price $8.70 per share Option covering 101,193 underlying common shares

Exercise price $5.74 per share Options covering 34,405 and 88,543 underlying common shares

Expiration date March 12, 2035 Option covering 101,193 underlying common shares

Expiration date November 25, 2035 Options covering 34,405 and 88,543 underlying common shares

Key Terms

Stock Option (Right to Buy), vested and became exercisable, continued service through each vesting date

3 terms

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy)"

vested and became exercisable financial

"1/4th of the option vested and became exercisable"

continued service through each vesting date financial

"subject to the Reporting Person's continued service through each vesting date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ASPE shares can Dalen Meeter's reported options buy?

The reported options cover 101,193, 34,405 and 88,543 common shares. The first option has an $8.70 exercise price; the other two have $5.74 exercise prices.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Meeter Dalen

(Last) (First) (Middle)

10835 ROAD TO THE CURE, SUITE 100

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
10/29/2026

3. Issuer Name and Ticker or Trading Symbol
Aspen Neuroscience, Inc. [ ASPE ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	03/12/2035	Common Stock	101,193	$8.7	D
Stock Option (Right to Buy)	(2)	11/25/2035	Common Stock	34,405	$5.74	D
Stock Option (Right to Buy)	(3)	11/25/2035	Common Stock	88,543	$5.74	D

Explanation of Responses:

1. The option was granted on March 13, 2025. 1/4th of the option vested and became exercisable on March 10, 2026, and 1/48th of the option shall vest equally and become exercisable on the same day of each month thereafter, subject to the Reporting Person's continued service through each vesting date.

2. The option was granted on November 26, 2025. 1/4th of the option vested and became exercisable on October 1, 2026, and 1/48th of the option shall vest and become exercisable on the same day of each month thereafter, subject to the Reporting Person's continued service through each vesting date.

3. The option was granted on November 26, 2025. 1/48th of the option shall vest and become exercisable on monthly anniversary beginning on December 20, 2025, subject to the Reporting Person's continued service through each vesting date.

Remarks:

Exhibit 24 - Power of Attorney

	By: /s/ Jeffrey L. Boerneke, as Attorney-in-Fact	10/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)